Skip to main content

Sound Advice: December 15, 2021

The U.S. Is Slipping Behind

In its early years, the semiconductor industry did not have many customers.  Few businesses in the 1950s could make use of the expensive new devices that allowed computers to function.  But one organization could: the federal government.

The first shipment from Fairchild Semiconductor – the company that helped create Silicon Valley – was for the computers inside the Air Force’s B-70 bomber.  The Minuteman missile soon needed semiconductors too, as did other Cold War weapons systems and NASA equipment.

Only the federal government tends to have the huge resources to make these investments.  After it does, private companies then use the fruits of these investments to develop innovative and profitable products, spurring economic growth and tax revenues that comfortably cover the cost of the original research.

The Defense Department built the original internet – and Google, Microsoft, Amazon, and others expanded it.  The National Institutes of Health funded laboratory experiments – and pharmaceutical companies created treatments based on them, including those for Covid-19.  There are similar stories in energy, automobiles, aviation, and other industries.

In recent decades, however, American investment in research and development (R&D) has lagged.  In 1964, U.S. federal spending on R&D reached a peak of 1.8% of Gross Domestic Product (GDP).  In the decades since, the rate of those expenditures has been reduced by nearly two-thirds.

The U.S. now spends a smaller share of national output on research and development than many other countries, ranking seventh on this measure. As a percentage of GDP, our R&D outlays are about half of those of China, which is the leader.  China is notably ambitious in this area, essentially copying the American strategy for building a strong economy, even as the U.S. has abandoned this strategy.

In The Wall Street Journal this week, Graham Allison, a Harvard professor, and Eric Schmidt, the former C.E.O. of Google, wrote, “In each of the foundational technologies of the 21st century — artificial intelligence, semiconductors, 5G wireless, quantum information science, biotechnology, and green energy — China could soon be the global leader.”

The semiconductor industry is a particularly good case study.  U.S. companies like Fairchild and Texas Instruments initially dominated, followed in later decades by Intel.  But the U.S. semiconductor industry has fallen behind, now making only about 12% of the world’s semiconductors, down from 37% in 1990.

Right now, U.S. companies make none of the most sophisticated chips.  Taiwan, however, is one of the leaders with those chips, which means that a disruption there – hardly out of the question, given China’s aggressive posture – could disrupt the global economy.

In June, the Senate passed a bill that could substantially increase American R&D efforts.  The bill included outlays of almost $250 billion over five years, including $52 billion for semiconductor makers.  The main purpose of the bill is to keep the U.S. from falling behind China.

The bill has yet to pass the House, though it is long overdue. 

N. Russell Wayne, CFP®

Any questions?  Please contact me at nrwayne@soundasset.com


Comments

Popular posts from this blog

Sound Advice: March 10, 2021

The ABCs of Stock Picking After decades of analyzing stocks (and funds) and investing for clients, I'm happy to share in plain English what's involved, what works, and what doesn't.  Keep in mind the reality that successful stock picking is an effort to maintain a good batting average. In baseball, a batting average of .300 or better is considered quite good.  With stock picking, you need to do better than .600, which means you have many more winners than losers. No one gets it right all of the time.  It's not even close.  Wall Street shops all have their recommended lists and the financial media regularly hawk 10 stocks to buy now. Following that road usually is a direct route to disaster.  Don't be tempted. Let's begin with the big picture: The stock market goes up and down over time, but the long-term trend is up.  When there's a rally under way, everyone feels like a genius.  When the market hits an air pocket, though, with few exception...

Sound Advice: January 3, 2025

2025 Market Forecasts: Stupidity Taken To An Extreme   If you know anything about stock market performance, you can only gag at the nonsense “esteemed forecasters” are now putting forth about the prospective path of stocks in the year ahead.   Our cousins in the UK would call this rubbish.   I would not be as kind. Leading the Ship of Fools is the forecast from the Chief Investment Strategist at Oppenheimer who is looking for a year-end 2025 level for the Standard & Poor’s Index of 7,100, a whopping 21% increase from the most recent standing.   Indeed, most of these folks are looking for double-digit gains.   Only two expect stocks to weaken. In the last 30 years, the market has risen by more than 20% only 15 times.   The exceptional span during that time was 1996-1999, which accounted for four of those jumps.   What followed in 2000 through 2002 was the polar opposite: 2000:      -9.1% 2001:     -11.9% ...

Sound Advice: June 17, 2020

Rock and a Hard Place Regardless of your age, impressions from childhood linger.  As the first days of summer approach, we all remember the feeling that accompanied the end of a school year.  Yet as much as many of us would like to believe we again have the summertime freedom to do as we wish, the reality is quite the opposite. Although months of confinement and limitations on social interaction have increased our personal discomfort and severely impacted the business community, our current situation is not analogous to the end of any school year.  It’s quite the opposite. There is every reason to continue wearing face masks, social distancing, and avoiding close contact with others.  Nothing suggests that we can modify our behavior significantly or resume patterns of daily living we enjoyed only a few months ago. There are no meaningful advances in medical treatments.  At best, there are attempts to combine different approaches...